Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 242Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Recurrence 35Burkitt Lymphoma 24Neoplasms 20Neoplasms, Plasma Cell 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Immunoglobulin Light-chain Amyloidosis 13Leukemia 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Lymphoma, B-Cell 6Smoldering Multiple Myeloma 5Nausea 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasm, Residual 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Amyloidosis 4

Interventions

tocilizumab 2siltuximab 2fludarabine phosphate 2fludarabine 2Interleukin 1 Receptor Antagonist Protein 2Cyclophosphamide 2AP 1903 reagent 2talquetamab 1obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Dexamethasone × 1 year × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡